These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37445274)

  • 1. Precision Delivery of Steroids as a Rescue Therapy for Gastrointestinal Graft-versus-Host Disease in Pediatric Stem Cell Transplant Recipients.
    Levitte S; Ganguly A; Frolik S; Guevara-Tique AA; Patel S; Tadas A; Klein O; Shyr D; Agarwal-Hashmi R; Beach L; Callard E; Weinacht K; Bertaina A; Thakor AS
    J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.
    Döring M; Cabanillas Stanchi KM; Lenglinger K; Treuner C; Gieseke F; Erbacher A; Mezger M; Vaegler M; Schlegel PG; Greil J; Bettoni da Cunha Riehm C; Faul C; Schumm M; Lang P; Handgretinger R; Müller I
    Stem Cells Dev; 2021 Mar; 30(5):234-246. PubMed ID: 33446053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of graft-versus-host disease after intestinal transplantation.
    Ganoza A; Mazariegos GV; Khanna A
    Curr Opin Organ Transplant; 2019 Apr; 24(2):199-206. PubMed ID: 30762668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature.
    Munneke JM; Spruit MJ; Cornelissen AS; van Hoeven V; Voermans C; Hazenberg MD
    Transplantation; 2016 Nov; 100(11):2309-2314. PubMed ID: 26714122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.
    Krejci M; Doubek M; Buchler T; Brychtova Y; Vorlicek J; Mayer J
    Ann Hematol; 2005 Oct; 84(10):681-5. PubMed ID: 16001244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.
    Sung AD; Hassan S; Cardona DM; Wild D; Nichols KR; Mehdikhani H; Balmadrid B; Detweiler CJ; Shealy M; Cirrincione C; Li Z; Poleski M; Dalton TE; Siamakpour-Reihani S; Chao NJ; Sullivan KM
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):734-740. PubMed ID: 29246821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Series of Precision Delivery of Methylprednisolone in Pediatric Inflammatory Bowel Disease: Feasibility, Clinical Outcomes, and Identification of a Vasculitic Transcriptional Program.
    Levitte S; Yarani R; Ganguly A; Martin L; Gubatan J; Nadel HR; Franc B; Gugig R; Syed A; Goyal A; Park KT; Thakor AS
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ileostomy for steroid-resistant acute graft-versus-host disease of the gastrointestinal tract.
    Turki AT; Bayraktar E; Basu O; Benkö T; Yi JH; Kehrmann J; Tzalavras A; Liebregts T; Beelen DW; Steckel NK
    Ann Hematol; 2019 Oct; 98(10):2407-2419. PubMed ID: 31338570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features, Treatment, and Outcome of Pediatric Steroid Refractory Acute Graft-Versus-Host Disease: A Multicenter Study.
    Verbeek AB; Jansen SA; von Asmuth EGJ; Lankester AC; Bresters D; Bierings M; Mohseny AB; Lindemans CA; Buddingh EP
    Transplant Cell Ther; 2022 Sep; 28(9):600.e1-600.e9. PubMed ID: 35717003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Ruxolitinib in Steroid-Refractory Graft versus Host Disease in Patients Undergoing Allogeneic Stem Cell Transplant.
    Javed H; Chaudhry Q; Shahbaz N; Khan MA; Iftikhar R; Yousaf M
    J Coll Physicians Surg Pak; 2022 Sep; 32(9):1225-1227. PubMed ID: 36089728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare Resource Utilization and Costs of Steroid-Associated Complications in Patients With Graft-Versus-Host Disease.
    Bell EJ; Yu J; Bhatt V; Bunner SH; Lal LS; Galvin J; Weisdorf D
    Transplant Cell Ther; 2022 Oct; 28(10):707.e1-707.e7. PubMed ID: 35483620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
    Uygun V; Karasu G; Daloğlu H; Öztürkmen S; Kılıç SÇ; Yalçın K; Çelen SS; Hazar V; Yeşilipek A
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28190. PubMed ID: 31981413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.
    Young JH; El Jurdi N; Rayes A; MacMillan ML; Holtan SG; Cao Q; Witte J; Arora M; Weisdorf DJ
    Transplant Cell Ther; 2022 Aug; 28(8):509.e1-509.e11. PubMed ID: 35577324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
    Zhang MY; Zhao P; Zhang Y; Wang JS
    PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
    MacMillan ML; Weisdorf DJ; Wagner JE; DeFor TE; Burns LJ; Ramsay NK; Davies SM; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(7):387-94. PubMed ID: 12171485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease.
    Ibrahimova A; Davies SM; Lane A; Jordan MB; Lake K; Litts B; Chaturvedi V; Owsley E; Myers KC; Nelson AS; Mehta PA; Marsh RA; Khandelwal P
    Pediatr Blood Cancer; 2021 Aug; 68(8):e28968. PubMed ID: 33861521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.